Drug Profile


Alternative Names: CAT-354

Latest Information Update: 26 Jul 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Icahn School of Medicine at Mount Sinai; LEO Pharma; MedImmune
  • Class Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma; Atopic dermatitis
  • Phase II Alopecia areata
  • Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 28 Jun 2017 Phase-III clinical trials in Atopic dermatitis (Monotherapy, Treatment-experienced) in Spain (SC) (EudraCT2016-004200-65)
  • 21 Jun 2017 AstraZeneca completes the phase II MESOS trial in Asthma in in Canada, Denmark, United Kingdom (NCT02449473)
  • 12 Jun 2017 LEO Pharma initiates enrolment in the phase III ECZTRA 2 trial in Atopic dermatitis (Monotherapy, Treatment-experienced) in USA (NCT03160885)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top